Articles tagged with Metastasis
The EPICUP® test, based on DNA analysis, can correctly diagnose CUP in 70% of cases, increasing the detection rate from traditional methods' 30%. This leads to the development of more specific treatments for these patients.
Researchers have found that lymph node metastases are not always the source of cancer's spread to other organs, and instead, distant metastases can originate directly from the primary tumor. In most cases (65%), both lymph node and distant metastases originated from the same cell type in the primary tumor, indicating independent origins.
Researchers have developed a method to visualize cancer metastasis in whole organs at the single-cell level, enabling early detection of dormant or resistant cancer cells. This breakthrough uses transparent mice and advanced imaging techniques to create 3-D maps of cancer cells throughout the body and organs.
Scientists in Japan develop a method to image cancer at the single-cell level, revealing cancerous colonies in detail. The technique allows researchers to track cancer cells as they multiply and metastasize, providing insight into metastatic pathways.
Researchers at CNIO have developed a technique to study melanoma progression in mice, revealing unknown mechanisms and identifying new markers of metastasis. The MIDKINE protein has been identified as a key factor in melanoma metastasis, representing a new therapeutic target.
Researchers developed an engineered opsonin protein to capture CTCs in the bloodstream, reducing detection time and increasing efficiency. The technology shows promise for improving cancer diagnostics by targeting specific carbohydrate molecules on CTCs.
A study published in Oncogene has shed new light on the molecular mechanisms of ovarian cancer spread. Researchers found that N-cadherin plays a key role in metastasis by enabling cancer cells to anchor to new sites in the body, and that disrupting this process may provide a therapeutic strategy.
Researchers at Georgia Institute of Technology have developed a new treatment that prevents cancer cells from migrating and spreading, known as metastasis. The treatment uses locally administered gold nanorods heated by a low-energy laser to target and destroy cancer cells' leg-like protrusions, effectively halting their migration.
Researchers found that dual-agent PET/MR with time of flight detects more bone metastases in breast and prostate cancer patients, improving detection accuracy and reducing radiation dose. The study used combined imaging agents <sup>18</sup> F-FDG and <sup>18</sup> F-NaF to enhance image quality.
Researchers found that metastatic breast cancer cells signal neighboring cells through the GLI transcription factor, allowing otherwise anchored cells to metastasize. The discovery highlights a promising link in the hedgehog signaling pathway, which can be targeted to reduce metastatic potential.
A team of NYU researchers has pinpointed a sugar modification in cells that spurs the spread of skin cancer, specifically melanoma. The study reveals that silencing FUT8 enzyme suppresses cancer onset and tumor dissemination in laboratory mice.
A phase III clinical trial found that alectinib, a next-generation ALK inhibitor, extended the median time to progression by about 15 months compared to crizotinib. Alectinib also caused fewer severe side effects and was more effective in preventing brain metastases.
Researchers have discovered a novel mechanism behind treatment resistance in brain metastatic breast cancers, and a potential treatment strategy that may overcome this resistance. Targeting the Human Epidermal Growth Factor Receptor 3 (HER3) protein has been shown to significantly slow tumor growth and improve survival.
Researchers at MD Anderson Cancer Center present two combination therapies that significantly shrink metastatic brain tumors in over half of patients with stage IV melanoma. The trials demonstrate the feasibility of conducting clinical trials for these patients and offer new hope for those with brain metastases.
Adding abiraterone acetate to standard hormonal therapy reduces the chance of death by 38% and doubles the median time until cancer worsens. Cancer growth is delayed by 18 months, but severe side effects like high blood pressure and liver enzyme abnormalities are more common with abiraterone.
A phase III clinical trial shows that a single radiation treatment is as effective as a full week of radiation in relieving spinal cord compression symptoms. This breakthrough finding could help patients with advanced cancer spend more time focusing on the things they enjoy, without compromising care.
A study by researchers at the University of Freiburg found that activation of FOXO can induce tumors in stem cells without initial DNA damage. The team discovered that signals inducing this cancer come from surrounding tissues, including epidermis.
The omentum, a layer of fat over intestines, liver, and stomach, has immune functions and secretes hormones related to obesity. It also plays a role in cancer development, serving as a breeding ground for aggressive tumors.
Researchers are conducting a Phase 1 clinical trial using Lutetium 177Lu-PSMA-617 to target PSMA in men with progressive prostate cancer. The therapy aims to deliver precise radiation therapy and shrink the cancer, even in cases without visible tumors.
Researchers have developed a chemical array technique that can identify and culture malignant stem-like cells within melanoma tumors. This allows for the creation of patient-specific models for individualized cancer treatment.
Researchers discovered a biochemical signaling process that causes densely packed cancer cells to break away and spread the disease. The combined use of two existing drugs disrupts this process, significantly slowing cancer's tendency to travel.
A recent study led by Massachusetts General Hospital researchers has identified a novel mechanism behind the resistance of HER2-positive breast cancer metastases to treatment. The study found that overexpression of the HER3 gene contributes to this resistance, and combining anti-HER2 and anti-HER3 therapies can slow tumor growth.
A CNIO researcher has been funded by the Melanoma Research Alliance to study brain metastasis in melanoma, focusing on blocking cancer cell spread by targeting the microenvironment. The goal is to develop a new concept of treating metastasis in personalized medicine.
New study reveals that immune cells trained to recognize cancer can exit one tumor and move to another to attack cancerous cells. The research sheds light on how immune therapies for cancer might work and suggests new approaches to developing anti-cancer immune therapies.
Research reveals how hypoxia leads to inhibition of miR-34a, a key tumor suppressor, promoting metastasis and EMT. The findings suggest that targeting this process with drugs could be a therapeutic approach for treating metastasizing colon tumors.
Primary colorectal tumors secrete VEGF-A, inducing CXCL1 and CXCR2-positive myeloid-derived suppressor cells to recruit at distant sites, establishing niches for future metastases. Liver-infiltrating MDSCs facilitate tumor cell survival in the new location.
A large study found that brachytherapy is a good option for many men with penile cancer, offering high survival rates and minimal impact on sexual and urinary function. The treatment allowed 85% of men to survive with their penis intact, with few cases requiring surgery due to side effects.
Researchers have developed a new microscopic technique to analyze single melanoma cells, which are often irregular and dark, making them difficult to investigate. The technique, using modified photoacoustic spectroscopy, can detect non-uniform cancer cells and track their spread.
Scientists at Scripps Research Institute discovered that invasive tumors can send out tumor cells earlier than thought, which may seed secondary tumors years later. The escaping cells enter the bloodstream by entering blood vessels deep within the dense tumor core, upending the long-held belief about metastatic cell origin.
A global understanding of breast cancer dissemination is crucial to improve treatment, and this study reveals that most metastases originate from a single precursor. Analyzing the genomic profile of metastases can help make therapeutic decisions, particularly for targeted treatments.
A recent study published in The Journal of Urology found that surgery to remove secondary tumor growths, called metastases, significantly improves survival rates for patients with late-stage kidney cancer. Patients who underwent surgery had a life expectancy of three to 12 years, compared to eight months and two years without surgery.
Researchers developed a laboratory technique to test the effectiveness of treatments for breast cancer metastases in bone, mimicking interactions between cancer cells and bone cells. The 'bone-in culture array' model found that danusertib inhibits bone metastasis while other drugs stimulate growth of slow-growing cancer cells.
A study published in JAMA Surgery found that certain breast cancer patients who achieve pathologic complete response (pCR) after chemotherapy have a low risk of developing local metastases, making them candidates for less invasive treatment options. These patients may be able to avoid follow-up surgery, including axillary surgery.
Researchers demonstrate that an aggressive combination of systemic therapy and local therapy can eliminate all detectable disease in selected patients with metastatic prostate cancer. One-fifth of the patients treated had no detectable disease, with undetectable PSA and normal testosterone levels after 20 months.
FAU researchers identified Zeb1 as a key factor that activates embryonic programme, leading to rapid dissemination and metastasis in pancreatic cancer. They also found that blocking Zeb1 reduces metastatic capacity in other tumour types.
A large study found patients with follicular and medullary thyroid cancer had the highest rate of bone lesions and fractures, and increased risk of death. Researchers suggest targeting this high-risk population with specific drugs to prevent or treat complications.
Researchers developed a method to isolate EVs from blood samples, enabling rapid analysis and potential personalized anticancer treatments. The technique uses nanoprobes to capture EVs within 15 minutes, offering an alternative to invasive methods.
Scientists have discovered that cancer can commandeers immature immune cells, called MDSCs, to facilitate its spread. MDSCs are normally part of the immune system's anti-tumor response but, under the influence of tumor-secreted cytokines, they can help tumors grow and metastasize.
Scientists have identified a biomarker, SMARCE1, that distinguishes poorly invasive tumors from those likely to spread and metastasize in early-stage breast cancer. This discovery enables doctors to tailor therapies designed to match the behavior of each patient's cancer, improving treatment outcomes.
A University of Colorado Cancer Center study found that knocking down the Jumonji protein KDM3A inhibits Ewing's Sarcoma metastasis. The researchers also discovered another protein, Melanoma Cell Adhesion Molecule (MCAM), plays a crucial role in the cancer's spread.
Researchers have identified pre-metastatic niches that prepare the ground for tumor cells to survive before invading other organs. Understanding this phenomenon could lead to new diagnostic and therapeutic tools to prevent cancer-related death.
Researchers at JAX have received $2.8 million in federal grants to develop better diagnostics and treatments for triple-negative breast cancer (TNBC). The studies aim to understand the underlying mechanisms that control metastasis and identify promising therapeutic targets.
Researchers found that breast cancer cells express reelin, a protein typically found in the brain, to disguise themselves and avoid detection. This allows them to form new deadly brain tumors, leading to high mortality rates among women with HER2-positive breast cancer.
Research at the University of Illinois Chicago found that blocking a protein on ovarian cancer cells can prevent its spread to other organs. The study's lead researcher believes this discovery could be a key to developing new treatments for the disease.
A recent study published in the American Journal of Roentgenology found that FDG PET/CT is a valuable imaging tool for treating lung cancer patients, especially when clinical suspicion or evidence of disease recurrence or metastasis is present. However, its routine use without clinical suspicion should be discouraged until its value fo...
Researchers discovered that weakly adherent cancer cells are more likely to migrate and invade other tissues compared to strongly adherent cells. This finding suggests that adhesion strength may serve as a general marker of metastatic cells.
Researchers found that cancer cells can spread through the extracellular matrix with optimal tissue stiffness. Drugs targeting ECM stiffness could prevent metastasis, providing a new approach to diagnostics and treatment.
A new study from Michigan Medicine identifies a protein in the microenvironment of metastatic breast cancer cells that promotes their spread. The researchers found that this protein, DDR2, plays a key role in fueling the growth and migration of cancer cells, and that inhibiting it may prevent metastasis.
Researchers compared stereotactic radiosurgery to whole-brain radiation for metastatic brain tumors and found that targeted therapy reduces cognitive decline and increases median survival rate by 218 days
The updated clinical guideline from the American Society for Radiation Oncology (ASTRO) underscores the safety and effectiveness of palliative radiation therapy (RT) for treating painful bone metastases. The guideline recommends optimal RT dosing schedules, including options for re-treatment, to provide pain relief, with a single 8-Gy ...
A QUT-led project has identified the mechanism by which melanoma cells switch from proliferative to invasive behavior, opening up new pathways for cancer treatment. The discovery reveals a specific regulatory pathway involving the NFIB-EZH2 axis, which could potentially be targeted with existing drugs.
A new technique separates circulating tumor cells from whole blood at a liquid-liquid interface, capturing 95% of CTCs in one minute. This method enables early detection and monitoring of metastatic disease, improving cancer treatment outcomes.
Researchers developed a new platform to switch MRI signals ON only in the presence of targeted diseases. The Nano MRI Lamp uses Magnetic Resonance Tuning (MRET) to control signal strength based on distance between magnetic materials.
A new gallium-68 labeled peptide BBN-RGD agent has been developed to target both gastrin-releasing peptide receptor and integrin αvβ3, providing dual-receptor targeting and advantages over single-receptor targeting. The agent has shown safety and effectiveness in detecting primary and metastatic prostate cancer lesions.
A study by the NRG Oncology Radiation Therapy Oncology Group found that adding antiandrogen therapy to radiation therapy can reduce the incidence of metastasis, death from prostate cancer, and overall deaths in patients with recurrent prostate cancer. The study showed a significant improvement in survival rates for patients treated wit...
A large study found that breast conserving therapy (BCT) is superior to mastectomy in early-stage breast cancer patients with no metastases. BCT, combined with radiation therapy, offers a survival advantage for patients aged over 50 years and those with comorbidity.
Researchers at the University of Illinois used a novel imaging technique to visualize microscopic shifts in metabolism and vesicle production in tumor cells. The study found that these changes can precede larger-scale events in the tumor environment, potentially preparing the way for cancerous cells to spread and metastasize.
Researchers at the University of Adelaide have identified a new microRNA that promotes cancer metastasis, leading to the development of a potential blood test for early detection. The discovery also reveals new targets for drugs that may inhibit cancer spread.
Researchers at the University of Missouri have discovered that luteolin, a natural compound found in herbs and vegetables, can inhibit the growth of triple-negative breast cancer cells in mice. The study found that luteolin reduced metastasis risk by preventing cancer cell migration and viability.
A study found that epigenetic changes, not DNA mutations, drive metastasis in pancreatic cancer cells. Researchers also identified a potential therapeutic target to block tumor formation in lab-grown cancer cells.